A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
Urothelial Carcinoma|Advanced Cancer
DRUG: RC48-ADC
Objective Response Rate （ORR）, Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR), up to 24 months
ORR of HER2-positive patients, Tumor response was assessed by investigator according to RECIST v1.1, up to 24 months|Progression Free Survival (PFS), Tumor response was assessed by investigator according to RECIST v1.1, up to 24 months|Duration of Response (DOR), DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier, up to 24 months|Disease control rate (DCR), DCR was defined as the proportion of patients who achieved an objective response or maintained stable disease during the study, up to 24 months|Overall Survival(OS), OS was defined as the time from the first study treatment to the date of death from any cause, up to 24 months|Adverse Events, Incidence of Adverse Events, 28 days after the last dose of study treatment
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.